Exelixis

A Broad and Expanding Pipeline At Exelixis, we are committed to making a meaningful impact on the lives of patients living with cancer. We are advancing an ambitious and pragmatic approach to drug development, to develop first-in-class and best-in-class therapies that will transform the treatment of cancer. We are transforming the challenges of our industry into opportunities for success by thinking larger, moving faster and charting our own course to our goal. Today we are a development-stage biotechnology company with an uncommonly rich pipeline of twelve compounds in clinical development with many more advancing to the clinic. As we look toward the future, we are building a portfolio of targeted compounds that modulate the activity of multiple disease-related pathways to achieve superior disease control and patient outcomes. Leveraging the Power of Our Platform We believe that the next generation of cancer therapies requires innovation in every part of our research, development and business organizations. At Exelixis, this means pursuing an uncommon approach to research and development, one that combines critical mass, speed, and unique approaches to create significant momentum toward our goals. With a library of more than 4 million compounds, we are able to rapidly identify high-quality leads for new drugs. Our extensive abilities in structure-based design and our approaches to pharmacodynamics and pharmacokinetics enable us to move these leads quickly forward. These capabilities are a resource that will enable us to file at least three investigational new drug applications (IND) each year for the foreseeable future. Even with an extensive and vigorous selection process to assure high-quality, we retained our speed, filing twleve INDs in the past three years. The strength and efficiency of our selection, screening and development processes provide a steady flow of promising product candidates. With so many opportunities, we believe that we have the ability to select only those compounds for which the data demonstrate clear first-in-class and best-in-class. This power is combined with a disciplined, pragmatic approach to managing our pipeline based on data and real medical need. Building the Momentum Toward or Goal We believe our commitment to significantly invest in preclinical development provides a more solid foundation on which to build new treatments for cancer. We believe the return on this investment will come in the form of higher clinical success rates and funding and partnership terms that allow us to retain increasing equity in the long-term value of our pipeline. Our strategic partnerships with GlaxoSmithKline, Bristol-Myers Squibb Company and Symphony Capital exemplify how our innovative approach to drug development is enabling us to create value for our shareholders and patients. Based in South San Francisco, California, Exelixis has over 550 dedicated employees who share a commitment to making a positive difference in the lives of patients with cancer and other serious diseases.

Contact Details: 210 East Grand Avenue P.O. Box 511 South San Francisco CA 94080 United States of America Tel: (650) 837-7000 Fax: (650) 837-8300 Email: msitton@exelixis.com WWW: www.exelixis.com/about.shtml

Loading...

Recent Publications by Exelixis:
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. PURPOSE: Mutations associated with resistance to kinase inhibition are an...	22nd May, 2008	Exelixis, Inc., South San Francisco, CA 94083, USA.	Clin Cancer Res. 2008 Apr 15;14(8):2465-75. DOI Direct Link
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. PURPOSE: Agents inhibiting the epidermal growth factor receptor (EGFR)...	5th October, 2007	Exelixis, Inc., South San Francisco, California 94083, USA.	Clin Cancer Res. 2007 Jun 15;13(12):3713-23. DOI Direct Link
Identification of small molecule ceramide kinase inhibitors using a homogeneous chemiluminescence high throughput assay. Lipid kinases have emerged as potentially important therapeutic targets in...	25th April, 2007	Exelixis, Inc., South San Francisco, CA 94083-0511, USA.	Assay Drug Dev Technol. 2007 Feb;5(1):65-73. DOI Direct Link
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Chk1 and Chk2 kinases are critically involved in modulating DNA damage...	10th April, 2007	Exelixis Inc., South San Francisco, California 94083, USA.	Cell Cycle. 2007 Jan 1;6(1):104-10. Epub 2007 Jan 7.
Target validation in drug discovery. The process of target validation identifies and assesses whether a...	9th December, 2006	Exelixis, Inc., South San Francisco, CA, USA.	Methods Mol Biol. 2007;356:367-77.
→View more Exelixis research publications.

BioNews Results for Exelixis:
Exelixis Announces October 6 Webcast of Presentation at the JMP Securities 3rd Annual Healthcare Focus Confere	Pharma Live:  Oct 5 2008 12:33AM Matching: exelixis
Exelixis files IND application for cancer drug	Pharmaceutical Business Review:  Oct 4 2008 3:25AM Matching: exelixis
Exelixis files investigational new drug application for anticancer compound	News-Medical.Net:  Oct 3 2008 12:59AM Matching: exelixis
Exelixis files investigational new drug application for anticancer compound	News-Medical.Net:  Oct 3 2008 12:59AM Matching: exelixis
Exelixis files application for cancer drug XL888	CNBC:  Oct 3 2008 1:07AM Matching: exelixis
Promote your company here: BioNewsCast - Press Release Distribution	→View more Exelixis news.

Exelixis Patents:
US Patent No.	Title
7413910	Multi-well apparatus
6642438	Melon promoters for expression of transgenes in plants
6630297	Methods of screening for agents that modulate the interaction of human ECT2 polypeptide with an ECT2 binding target
6627746	Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
6599717	Invertebrate vascular endothelial growth factor receptor
→View more Exelixis patents.

Exelixis (EXEL) Financial information Links from Barchart
EXEL Quote from from Barchart.com
EXEL Chart from from Barchart.com
EXEL Profile from from Barchart.com
EXEL Opinion from from Barchart.com
→View more Exelixis finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 13 individuals from Exelixis using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 167 times since April 2007, the link to the organisation's website has been followed 28 times

Recent Search Terms used to find this page: exelixis.com | exelixis com | Exelixis and Ect2 | exelixis.com | exelixis.com | exelixis.com e-mail address | .

Search for more companies in South San Francisco

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Exelixis